Thiazoles are very important functional groups in medicinal chemistry. They act as ligands on a variety of biological matrices. Thiazoles are used in a wide range of therapeutic applications, such as antibacterial, antiretroviral, antifungal, antiallergic, antihypertensive, pain treatment, and to control symptoms of schizophrenia.
vTv Therapeutics announces FDA submission for first phase 3 study of Cadisegliatin in patients with type 1 diabetes. Cadisegliatin (TTP399) is developed as an adjunctive therapy to insulin for the treatment of type 1 diabetes, and the phase 3 trial evaluates its safety and efficacy.
Glucokinase (GK) is mainly concentrated in liver cells, and involved in the regulation of glucose metabolism. Cadisegliatin (TTP399) is a liver-selective glucosekinase activator with a mechanism of action different from that of antidiabetic drugs. It binds to the allosteric site of GK and restores innate glucose-regulating capacity of the liver, not disrupting the interaction between GK and GKRP. Cadisegliatin previously received a Breakthrough Therapy designation from the U.S. FDA.